10-5-03

ULL on STN
CLM What is claimed is:

1. A method of treating depression comprising administering to a patient a pharmacologically effective dose of an opioid antagonist selected from the group consisting of **naltrexone**, **naloxone**, their pharmacologically effective salts and esters, or combinations thereof, and a pharmacologically effective dose of a compound selected from the group consisting of one or more nontricyclic antidepressants exhibiting serotonin reuptake inhibition in the synapses of the central nervous system, their pharmacologically effective salts and esters, or combinations thereof.

2. The method of claim 1, wherein said opioid antagonist is **naltrexone** hydrochloride.

3. The method of claim 1, wherein the pharmacologically effective dose of said opioid antagonist is a molar equivalent weight to 25 mg. of **naltrexone** hydrochloride.

4. The method of claim 1, wherein the pharmacologically effective dose of said opioid antagonist is a molar equivalent weight to 50 mg. of **naltrexone** hydrochloride.

5. The method of claim 2, wherein the pharmacologically effective dose of **naltrexone** hydrochloride is 10 mg. given at bedtime for the first three days of treatment, 10 mg. in the morning on the fourth day of treatment, and thereafter when no bedtime sleepiness is evident, 25 mg.

8. The method of claim 1, wherein said depressed patient is concomitantly being treated for a disorder selected form the group consisting of anxiety, mania, and convulsive disorder, wherein said anxiety is being treated with a benzodiazepine compound, said mania is being treated with **lithium** and said convulsive disorder is being treated with an anticonvulsive active compound.

9. A composition for treating depression, comprising a combination of a pharmacologically effective dose of a compound selected from the group consisting of **naltrexone**, **naloxone**, their pharmacologically effective salts and esters, or combinations thereof, and a pharmacologically effective dose of a compound selected from the group consisting of one or more nontricyclic antidepressants exhibiting serotonin reuptake inhibition in the synapses of the central nervous system, their pharmacologically effective salts and esters, or combinations thereof.

11. The composition of claim 9, wherein said opioid antagonist is **naltrexone** hydrochloride and said nontricyclic antidepressant is selected form the group consisting of sertraline, fluoxetine, their pharmacologically effective salts and esters, and combinations thereof.

ACCESSION NUMBER: 96:36589 USPATFULL
TITLE: Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
INVENTOR(S): Dante, Lee G., Merion Station, PA, United States
PATENT ASSIGNEE(S): Nagle, John S., Riverdale, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5512593		19960430	
APPLICATION INFO.:	US 1993-31096		19930302	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: MacMillan, Keith
LEGAL REPRESENTATIVE: Nagle, John S.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

STN

CLM What is claimed is:

1. A method of treating depression associated with alcoholism, comprising administering to a patient a pharmacologically effective dose of an opioid antagonist having a pentacyclic nucleus structurally analogous to **naltrexone**, **naloxone**, and **nalmefene**, and a phatmacologically effective dose of an antidepressant compound selected from the group consisting of a serotonin reuptake inhibitor, a tricyclic antidepressant, an atypical antidepressant, and lithiun, their pharmacologically effective salts and esters, or combinations thereof.

2. The method of claim 1, wherein said opioid antagonist is selected from the group consisting of **naltrexone** hydrochloride, **nalmefene**, and the salt and esters of **nalmefene**.

3. The method of claim 1, wherein the pharmacologically effective dose of said opioid antagonist is a molar equivalent weight to 25 mg. of **naltrexone** hydrochloride.

4. The method of claim 1, wherein the pharmacologically effective dose of said opioid antagonist is a molar equivalent weight to 10 mg. of **naltrexone** hydrochloride.

7. The method of claim 1, wherein said depressed patient is concomitantly being treated for a disorder selected from the group consisting of anxiety, mania, and convulsive disorder, wherein said anxiety disorder is being treated with a benzodiazepine compound, said mania is being treated with **lithium** and said convulsive disorder is being treated with an anticonvulsive active compound.

ACCESSION NUMBER:	2000:27987 USPATFULL
TITLE:	Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures
INVENTOR(S):	Dante, Lee G., Merion Station, PA, United States
PATENT ASSIGNEE(S):	Nagle, John S., San Diego, CA, United States (U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6034091		20000307
APPLICATION INFO.:	US 1998-165549		19981002 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-755795, filed on 28 Aug 1996, now patented, Pat. No. US 5856332 which is a division of Ser. No. US 1995-560820, filed on 20 Nov 1995, now patented, Pat. No. US 5817665 which is a division of Ser. No. US 1993-31096, filed on 2 Mar 1993, now patented, Pat. No. US 5512593

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Jarvis, William R. A.
LEGAL REPRESENTATIVE:	Nagle, Esq., John S.
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
LINE COUNT:	443

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 9 USPATFULL on STN

CLM What is claimed is:

13. A method as in claim 6, wherein said medication is chosen from the group consisting of disulfiram, antabuse, chiorpromazine, thorazine, oxycontin, percocet, darvon, darvocet, vicodin, lorcet, dialaudid, demerol, **nalmefene**, **valium**, librium, Xanax, **halcyon**, Pro Som, and medicament including gamma vinyl GABA.

20. A method as in claim 14, wherein said medication is chosen from the group consisting of disulfiram, antabuse, chlorpromazine, thorazine, oxycontin, percocet, darvon, darvocet, vicodin, lorcet, dialaudid, demerol, **nalmefene**, **valium**, librium, Xanax, **halcyon**, Pro Som, and medicament including gamma vinyl GABA.

ACCESSION NUMBER:	2002:344838 USPATFULL		
TITLE:	Automatic sobriety training and reconditioning system		
INVENTOR(S):	Gumpert, Ron, Smithtown, NY, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198574	A1	20021226
APPLICATION INFO.:	US 2002-177359	A1	20020622 (10)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2001-300117P		20010622 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Jennifer Meredith, Suite 7720, 350 Fifth Ave., New York, NY, 10118		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	566		

L7 ANSWER 6 OF 9 USPATFULL on STN

CLM What is claimed is:

12. The method of claim 1 wherein the Impulse Control Disorder is an alcohol abuse/dependence condition and the compound is used in conjunction with one or more other drug compounds selected from the group consisting of **naltrexone**, serotonin reuptake inhibitors, and other antidepressants.

13. The method of claim 1 wherein the Impulse Control Disorder is a behavioral addiction condition and the compound is used in conjunction with one or more other drug compounds selected from the group consisting of serotonin reuptake inhibitors, **lithium**, valproic acid or divalproex sodium, other antidepressants, **naltrexone**, atypical antipsychotics, and other mood stabilizers.

14. The method of claim 1 wherein the Impulse Control Disorder is a paraphilias/sexual addiction condition and the compound is used in conjunction with one or more other drug compounds selected from the group consisting of serotonin reuptake inhibitors, **lithium**, divalproex sodium/valproic acid, antiandrogen agents, other antidepressants, and other mood stabilizers.

ACCESSION NUMBER: 2001:160986 USPATFULL
TITLE: Use of sulfamate derivatives for treating impulse control disorders
INVENTOR(S): McElroy, Susan L., Cincinnati, OH, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001023254	A1	20010920
	US 6323236	B2	20011127
APPLICATION INFO.:	US 2000-506991	A1	20000218 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FROST BROWN TODD, LLC, 2200 PNC CENTER, 201 E. FIFTH STREET, CINCINNATI, OH, 45202
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 55096-26-9 REGISTRY
CN Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5.alpha.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (-)-Nalmefene
CN 6-Deoxo-6-methylenenaltrexone
CN 6-Desoxy-6-methylenenaltrexone
CN JF 1
CN **Nalmefene**
CN Nalmetrene
CN ORF 11676
FS STEREOSEARCH
MF C21 H25 N O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

199 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
201 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 16590-41-3 REGISTRY
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Morphinan-6-one, 17-(cyclopropylmethyl)-4,5.alpha.-epoxy-3,14-dihydroxy- (8CI)
OTHER NAMES:
CN 1-N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynormorphinone
CN Depotrex
CN EN 1639
CN N-Cyclopropylmethylnoroxymorphone
CN Naltrel
CN **Naltrexone**
CN Nemexin
CN ReVia
CN UM 792
FS STEREOSEARCH
MF C20 H23 N O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1684 REFERENCES IN FILE CA (1907 TO DATE)
42 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1686 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 465-65-6 REGISTRY
CN Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5.alpha.)-(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Morphinan-6-one, 17-allyl-4,5.alpha.-epoxy-3,14-dihydroxy- (8CI)
CN Normorphinone, N-allyl-7,8-dihydro-14-hydroxy- (7CI)
OTHER NAMES:
CN (-)-Naloxone
CN 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one
CN 9: PN: WO03037310 FIGURE: 4 claimed sequence
CN l-Naloxone
CN **Naloxone**
CN NSC 70413
FS STEREOSEARCH
DR 5592-87-0
MF C19 H21 N O4
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4888 REFERENCES IN FILE CA (1907 TO DATE)
26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4890 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2003 ACS on STN
RN 219756-54-4 REGISTRY
CN Morphinan-6-one, 17-butyl-7,8-didehydro-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H23 N O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2003 ACS on STN
RN 219756-53-3 REGISTRY
CN Morphinan-6-one, 7,8-didehydro-4,5-epoxy-17-ethyl-3,14-dihydroxy-, (5.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H19 N O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2003 ACS on STN
RN 30964-47-7 REGISTRY
CN Morphinan-6-one, 7,8-didehydro-4,5-epoxy-3,14-dihydroxy-17-(2-phenylethyl)-

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 99294-93-6 REGISTRY
CN Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (2:1)
OTHER NAMES:
CN **Ambien**
CN Ivadal
CN Niotal
CN SL 800750-23N
CN Stilnoct
CN Stilnox
CN Zolpidem hemitartrate
CN Zolpidem tartrate
FS STEREOSEARCH
MF C19 H21 N3 O . 1/2 C4 H6 O6
SR US Adopted Names Council
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CHEMCATS, CIN, CSCHEM, DIOGENES, DRUGPAT, DRUGUPDATES, EMBASE, HSDB*, IPA, MRCK*, PHAR, PHARMASEARCH, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 82626-48-0
CMF C19 H21 N3 O



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



38 REFERENCES IN FILE CA (1907 TO DATE)
38 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s halcyon/cn
L4              0 HALCYON/CN
```

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 28911-01-5 REGISTRY
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4H-s-Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(o-chlorophenyl)-1-methyl- (8CI)
OTHER NAMES:
CN 8-Chloro-1-methyl-6-(o-chlorophenyl)-4H-s-triazolo[4,3-a][1,4]benzodiazepine
CN D II-18-2
CN **Halcion**
CN Novodorm
CN Songar
CN Triazolam
CN U 33030
FS 3D CONCORD
MF C17 H12 Cl2 N4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1128 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1132 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 439-14-5 REGISTRY
CN 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-phenyl-7-chloro-1,3-dihydro-1H-1,4-benzodiazepin-2-one
CN 1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
CN 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
CN 7-Chloro-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepine
CN 7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
CN 7-Chloro-1-methyl-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one
CN 7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one
CN Alboral
CN Aliseum
CN Alupram
CN Amiprol
CN An-Ding
CN Anlin
CN Ansiolin
CN Ansiolisina
CN Antenex
CN Anxionil
CN Apaurin
CN Apo-diazepam
CN Apozepam
CN Armonil
CN Arzepam
CN Assival
CN Atensine
CN Atilen
CN Azedipamin
CN Baogin
CN Benzopin
CN Best
CN Betapam
CN Bialzepam
CN Britazepam
CN Calmocitene
CN Calmod
CN Calmpose
CN Caudel
CN Centrazepam
CN Cercine
CN Ceregulart
CN Chuansuan
CN D-Pam
CN Desconet
CN Desloneg
CN Diacepan
CN Diaceplex
CN Dialag
CN Dialar
CN Diapam
CN Diapax
CN Diapine
CN **Valium**
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS 3D CONCORD
DR 11100-37-1, 53320-84-6
MF C16 H13 Cl N2 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,

BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGPAT, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11803 REFERENCES IN FILE CA (1907 TO DATE)
60 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
11811 REFERENCES IN FILE CAPLUS (1907 TO DATE)
55 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

Uploading 10000113.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,CH2

G2 Cb,Cy,Ak

G3 O,CH2,NH2

7.70 169.84

FILE 'STNGUIDE' ENTERED AT 17:47:46 ON 05 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 28, 2003 (20031128/UP).

=> d his

(FILE 'HOME' ENTERED AT 17:42:19 ON 05 DEC 2003)

FILE 'REGISTRY' ENTERED AT 17:43:45 ON 05 DEC 2003
L1 STRUCTURE UPLOADED
L2 7 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 17:46:40 ON 05 DEC 2003
L3 2 S L2

FILE 'STNGUIDE' ENTERED AT 17:47:46 ON 05 DEC 2003

=>

, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Morphinan-6-one, 7,8-didehydro-4,5-epoxy-3,14-dihydroxy-17-(2-phenylethyl)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (salt)
FS STEREOSEARCH
MF C24 H23 N O4 . x C4 H6 O6

CM 1

CRN 26568-66-1
CMF C24 H23 N O4

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



L2 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2003 ACS on STN
RN 26568-66-1 REGISTRY
CN Morphinan-6-one, 7,8-didehydro-4,5.alpha.-epoxy-3,14-dihydroxy-17-phenethyl- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H23 N O4
CI COM
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2003 ACS on STN
RN 26451-92-3 REGISTRY
CN Morphinan-6-one, 17-allyl-7,8-didehydro-4,5.alpha.-epoxy-3,14-dihydroxy- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H19 N O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2003 ACS on STN
RN 26451-54-7 REGISTRY
CN Morphinan-6-one, 7,8-didehydro-4,5.alpha.-epoxy-3,14-dihydroxy-17-isopropyl- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H21 N O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2003 ACS on STN
RN 26451-53-6 REGISTRY
CN Morphinan-6-one, 7,8-didehydro-4,5-epoxy-3,14-dihydroxy-17-propyl-, (5.alpha.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Morphinan-6-one, 7,8-didehydro-4,5.alpha.-epoxy-3,14-dihydroxy-17-propyl- (8CI)
FS STEREOSEARCH
MF C19 H21 N O4
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
IT 508-54-3P 16251-65-3P 26568-62-7P 26568-63-8P 26568-64-9P
26568-65-0P **26568-66-1P** 26615-25-8P 26615-26-9P
26615-27-0P 26693-04-9P 26834-16-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT **26568-66-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 26568-66-1 CAPLUS
CN Morphinan-6-one, 7,8-didehydro-4,5.alpha.-epoxy-3,14-dihydroxy-17-phenethyl- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 1970:121761 CAPLUS
DOCUMENT NUMBER: 72:121761
TITLE: 14-Hydroxynormorphinones
INVENTOR(S): Seki, Isao
PATENT ASSIGNEE(S): Sankyo Co., Ltd.
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1938219	A	19700212	DE 1969-1938219	19690724
CH 524609	A	19720630	CH 1969-524609	19690725
CH 532581	A	19730228	CH 1972-2350	19690725
GB 1260699	A	19720119	GB 1969-1260699	19690728

PRIORITY APPLN. INFO.: JP 1968-52829 19680726
JP 1968-52830 19680726
JP 1968-52831 19680726

=>

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
IT 125-29-1P 466-99-9P 508-54-3P 2302-66-1P 7239-98-7P
26451-53-6P 41135-98-2P 150843-48-4P **219756-53-3P**
219756-54-4P
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(transformations of morphine, codeine and analogs by Bacillus sp.)
IT **26451-53-6P 219756-53-3P 219756-54-4P**
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(transformations of morphine, codeine and analogs by Bacillus sp.)
RN 26451-53-6 CAPLUS
CN Morphinan-6-one, 7,8-didehydro-4,5-epoxy-3,14-dihydroxy-17-propyl-, (5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219756-53-3 CAPLUS
CN Morphinan-6-one, 7,8-didehydro-4,5-epoxy-17-ethyl-3,14-dihydroxy-, (5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219756-54-4 CAPLUS
CN Morphinan-6-one, 17-butyl-7,8-didehydro-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER:	1998:775026 CAPLUS
DOCUMENT NUMBER:	130:110434
TITLE:	Transformations of morphine, codeine and their analogs by Bacillus sp.
AUTHOR(S):	Madyastha, K. M.; Reddy, G. V. B.; Sridhar, G. R.
CORPORATE SOURCE:	Department of Organic Chemistry, Bioorganic Section, Indian Institute of Science, Bangalore, 560 012, India
SOURCE:	Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1998), 37B(8), 749-753 CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER:	National Institute of Science Communication, CSIR
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 130:110434
REFERENCE COUNT:	19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

reuptake inhibitor

INVENTOR(S):	Dante, Lee G., Merion Station, PA, United States		
PATENT ASSIGNEE(S):	Nagle, John S., Riverdale, MD, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5512593		19960430
APPLICATION INFO.:	US 1993-31096		19930302 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cintins, Marianne M.		
ASSISTANT EXAMINER:	MacMillan, Keith		
LEGAL REPRESENTATIVE:	Nagle, John S.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	496		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
     (FILE 'HOME' ENTERED AT 14:07:00 ON 09 DEC 2003)

     FILE 'USPATFULL' ENTERED AT 14:07:34 ON 09 DEC 2003
L1          2148 S NALTREXONE OR NALOXONE OR NALMEFENE
L2             0 S L1.CLM
L3             0 S L1.CLM.
L4           279 S L1/CLM
L5        142588 S VALIUM OR LITHIUM OR LACION OR HALCYON OR AMBIEN
L6         23562 S L5/CLM
L7             9 S L4 AND L6

=> save all
ENTER NAME OR (END):l10000113a/l
L# LIST L1-L7 HAS BEEN SAVED AS 'L10000113A/L'

=>
```

L7 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:247472 USPATFULL
TITLE: Method for classifying and treating physiologic brain imbalances using quantitative EEG
INVENTOR(S): Suffin, Stephen, Sherman Oaks, CA, United States
PATENT ASSIGNEE(S): CNS Response, Thousand Oaks, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6622036	B1	20030916	
APPLICATION INFO.:	US 2000-501149		20000209	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Nasser, Robert L.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2140

L7 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:106801 USPATFULL
TITLE: Inhibitors of ABC drug transporters at the blood-brain barrier
INVENTOR(S): Schoenhard, Grant L., San Carlos, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003073713	A1	20030417	
APPLICATION INFO.:	US 2001-113	A1	20011030	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-244482P	20001030	(60)
	US 2000-245110P	20001101	(60)
	US 2000-245235P	20001103	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCANDREWS HELD & MALLOY, LTD, 500 WEST MADISON STREET, SUITE 3400, CHICAGO, IL, 60661
NUMBER OF CLAIMS: 393
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 3275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:17938 USPATFULL
TITLE: Methods of treating neurological disorders
INVENTOR(S): Gullans, Steven R., Natick, MA, UNITED STATES
Sarang, Satinder, Boston, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003013692	A1	20030116	
APPLICATION INFO.:	US 2002-52691	A1	20020118	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-262720P	20010119	(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C., One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 151
EXEMPLARY CLAIM: 1
LINE COUNT: 1145
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2002:344838 USPATFULL
TITLE: Automatic sobriety training and reconditioning system
INVENTOR(S): Gumpert, Ron, Smithtown, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198574	A1	20021226
APPLICATION INFO.:	US 2002-177359	A1	20020622 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-300117P	20010622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jennifer Meredith, Suite 7720, 350 Fifth Ave., New York, NY, 10118
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 566

L7 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2002:84928 USPATFULL
TITLE: Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
INVENTOR(S): van Lengerich, Bernhard H., Plymouth, MN, UNITED STATES
PATENT ASSIGNEE(S): General Mills, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002044968	A1	20020418
APPLICATION INFO.:	US 2001-782320	A1	20010213 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-269763, filed on 17 May 1999, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Douglas J. Taylor, Esq., General Mills, Inc., P.O. Box 1113, Minneapolis, MN, 55440
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2709

L7 ANSWER 6 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2001:160986 USPATFULL
TITLE: Use of sulfamate derivatives for treating impulse control disorders
INVENTOR(S): McElroy, Susan L., Cincinnati, OH, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001023254	A1	20010920
	US 6323236	B2	20011127
APPLICATION INFO.:	US 2000-506991	A1	20000218 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FROST BROWN TODD, LLC, 2200 PNC CENTER, 201 E. FIFTH STREET, CINCINNATI, OH, 45202
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2000:27987 USPATFULL
TITLE: Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures
INVENTOR(S): Dante, Lee G., Merion Station, PA, United States
PATENT ASSIGNEE(S): Nagle, John S., San Diego, CA, United States (U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6034091		20000307
APPLICATION INFO.:	US 1998-165549		19981002 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-755795, filed on 28 Aug 1996, now patented, Pat. No. US 5856332 which is a division of Ser. No. US 1995-560820, filed on 20 Nov 1995, now patented, Pat. No. US 5817665 which is a division of Ser. No. US 1993-31096, filed on 2 Mar 1993, now patented, Pat. No. US 5512593
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Nagle, Esq., John S.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 1998:122416 USPATFULL
TITLE: Composition and method of treating depression using naloxone or naltrexone in combination with a serotonin reuptake inhibitor
INVENTOR(S): Dante, Lee G., Merion Station, PA, United States
PATENT ASSIGNEE(S): Nagle, John S., Thousand Oaks, CA, United States (U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5817665		19981006
APPLICATION INFO.:	US 1995-560820		19951120 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-31096, filed on 2 Mar 1993, now patented, Pat. No. US 5512593
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Nagle, John S.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 9 USPATFULL on STN
ACCESSION NUMBER: 96:36589 USPATFULL
TITLE: Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin

L10 ANSWER 15 OF 64 USPATFULL on STN
DETD . . . covalently attached to the polypeptide. Acive agents may be selected from the list in TABLE 1, either alone or in **combination** with other agents on the list.
TABLE 1

abacavir sulfate
abarelix
acarbose
Acetaminophen
Acetaminophen; Codeine phosphate
Acetaminophen; Propoxyphene napsylate
. . . tannate
Clozapine
Colestipol HCL
conivaptan
Cyclobenzaprine HCL
Cyclophosphamide
Cyclosporine
dalteparin sodium
dapitant
desmopressin acetate
Desogestrel; ethinyl estradiol
Dextroamphetamine sulfate
dextromethorphan
Diazepam
ABT 594
Diclofenac sodium
diclofenac sodium, misoprostol
Dicyclomine HCL
didanosine
Digoxin
diltiazem hydrochloride
Dipyridamole
divalproex sodium
d-methylphenidate
dolasetron mesylate monohydrate
. . . bromide
venlafaxine hydrochloride
Verapamil HCL
vinorelbine tartrate
Vitamin B12
Vitamin C
voriconazole
Warfarin Sodium
xaliproden
zafirlukast
zaleplon
zenarestat
zidovudine
zolmitriptan
Zolpidem
bleomycin
Phytoseterol
paclitaxel
Flutiasone
Fluorouracil
Pseudoephedrine
A 78773
AGI 1067

BCX CW1812
BMS CW188667
BMS CW193884
BMS CW204352
BPI 21
CD11a
CEB 925
Propofol
GT 102279
Recombinant hepatitis vaccine
L 159282
LFA3TIP
Daily Multi Vit
Erythromycn/Sulfsx
Ethinyl estradiol; Desogestrel
Lithium Carbonate
LYM 1
Methylprednisolone Sodium
succinate
rotavirus vaccine
saquinavir mesylate
arginine
heparin
Thymosin alpha
montelukast sodium and
fexofenadine hydrochloride
Iodothyronine
. . . and hydrocodone
bitarirate
Chlorpheniramine maleate,
hydrocodone bitartrate and
pseudoephedrine
Guaifenesin and hydrocodone
Ibuprofen and hydrocodone
Chlorpheniramine polistirex and
hydrocodone polystirex
naltrexone

PI US 2002099013 A1 20020725